PMID- 22751030 OWN - NLM STAT- MEDLINE DCOM- 20130605 LR - 20121205 IS - 1536-5409 (Electronic) IS - 0749-8047 (Linking) VI - 29 IP - 1 DP - 2013 Jan TI - Treatment of chronic, intractable pain with a conventional implantable pulse generator: a meta-analysis of 4 clinical studies. PG - 78-85 LID - 10.1097/AJP.0b013e318247309a [doi] AB - OBJECTIVE: To provide further short-term (6 mo) and long-term (1 y) evidence for the use of spinal cord stimulation (SCS) with a conventional implantable pulse generator in the management of chronic, intractable pain. MATERIALS AND METHODS: We conducted a meta-analysis of 4 prospective, multicenter studies that collected outcome data from patients implanted with SCS to treat chronic pain of the trunk and/or limbs (Genesis IPG system). Two of these were conducted as long-term studies lasting 1 year, and 2 as shorter term studies lasting 6 months. A total of 300 patients from 28 investigational sites were prospectively evaluated for efficacy at 3 months after implant and safety at 6 months after implant. None of the sites participated in more than one study. Outcome measures included patient-reported percent of pain relief, patient satisfaction, quality of life improvement, pain evaluation (0 to 10 rating), pain relief rating, Short-Form McGill Pain Questionnaire, visual analog scale, the Short Form-36, and the total number of adverse events (AEs). RESULTS: At 3 months after implantation of the permanent system, 75.4% of the patients (190/252) reported a 50% or greater pain relief as determined by the patient-reported degree of pain relief. Similarly, assessment of patient satisfaction with SCS therapy showed that 86.1% of patients (217/252) in all 4 studies were satisfied or very satisfied with the therapy at 3 months. In the 2 long-term studies, 80.9% of patients (140/173) were satisfied or very satisfied with the therapy at the 1-year evaluation point. Quality-of-life (QoL) data indicated that at 3 months after implant, 77.8% of patients (196/252) reported QoL as improved or greatly improved. Similarly, QoL was improved or greatly improved for 74.0% patients in the long-term study at 1 year (128/173). In the safety analysis, AEs were reviewed for all 4 studies. A total of 190 AEs were reported in 117 of 300 patients during all studies. CONCLUSIONS: This analysis provides further evidence of the safety and effectiveness of SCS in treating chronic intractable pain of the trunk and/or limbs. Specifically, it underscores a high level of effectiveness and acceptable safety concerns in the use of nonrechargeable SCS devices. FAU - Slavin, Konstantin V AU - Slavin KV AD - Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL 60612, USA. kslavin@uic.edu FAU - Vaisman, Julien AU - Vaisman J FAU - Pollack, Kenneth L AU - Pollack KL FAU - Simopoulos, Thomas T AU - Simopoulos TT FAU - Kowlowitz, Edward AU - Kowlowitz E FAU - Weinand, Martin E AU - Weinand ME FAU - Norregaard, Thorkild V AU - Norregaard TV CN - Genesis Study Investigators LA - eng PT - Journal Article PT - Meta-Analysis PT - Multicenter Study PL - United States TA - Clin J Pain JT - The Clinical journal of pain JID - 8507389 SB - IM MH - Electric Stimulation Therapy/*instrumentation/*statistics & numerical data MH - Equipment Design MH - Equipment Failure Analysis MH - *Evidence-Based Medicine MH - Female MH - Humans MH - Male MH - Pain, Intractable/*epidemiology/*prevention & control MH - Patient Satisfaction/statistics & numerical data MH - Prevalence MH - Prostheses and Implants/*statistics & numerical data MH - Risk Factors MH - Treatment Outcome EDAT- 2012/07/04 06:00 MHDA- 2013/06/06 06:00 CRDT- 2012/07/04 06:00 PHST- 2012/07/04 06:00 [entrez] PHST- 2012/07/04 06:00 [pubmed] PHST- 2013/06/06 06:00 [medline] AID - 10.1097/AJP.0b013e318247309a [doi] PST - ppublish SO - Clin J Pain. 2013 Jan;29(1):78-85. doi: 10.1097/AJP.0b013e318247309a.